Cost implications of implementation of pathogen-inactivated platelets.

ABSTRACT:

Background

Pathogen inactivation (PI) is a new approach to blood safety that may introduce additional costs. This study identifies costs that could be eliminated, thereby mitigating the financial impact.

Study design and methods

Cost information was obtained from five institutions on tests and procedures (e.g., irradiation) currently performed, that could be eliminated. The impact of increased platelet (PLT) availability due to fewer testing losses, earlier entry into inventory, and fewer outdates with a 7-day shelf life were also estimated. Additional estimates include costs associated with managing (1) special requests and (2) test results, (3) quality control and proficiency testing, (4) equipment acquisition and maintenance, (5) replacement of units lost to positive test

SUBMITTER: McCullough J 

PROVIDER: S-EPMC4691315 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature